Current File : /var/www/html/sljcon/public/rlyldfr/cache/10ca07b67ab82d4d3e01dca7eaf4935d
a:5:{s:8:"template";s:3196:"<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html lang="en">
<head profile="http://gmpg.org/xfn/11">
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<title>{{ keyword }}</title>
<style rel="stylesheet" type="text/css">@font-face{font-family:Roboto;font-style:normal;font-weight:400;src:local('Roboto'),local('Roboto-Regular'),url(https://fonts.gstatic.com/s/roboto/v20/KFOmCnqEu92Fr1Mu4mxP.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(https://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfBBc9.ttf) format('truetype')} html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}a{background-color:transparent}a:active,a:hover{outline:0}h1{margin:.67em 0;font-size:2em}/*! Source: https://github.com/h5bp/html5-boilerplate/blob/master/src/css/main.css */@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}p{orphans:3;widows:3}} *{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}h1{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}h1{margin-top:20px;margin-bottom:10px}h1{font-size:36px}p{margin:0 0 10px}@-ms-viewport{width:device-width}html{height:100%;padding:0;margin:0}body{font-weight:400;font-size:14px;line-height:120%;color:#222;background:#d2d3d5;background:-moz-linear-gradient(-45deg,#d2d3d5 0,#e4e5e7 44%,#fafafa 80%);background:-webkit-linear-gradient(-45deg,#d2d3d5 0,#e4e5e7 44%,#fafafa 80%);background:linear-gradient(135deg,#d2d3d5 0,#e4e5e7 44%,#fafafa 80%);padding:0;margin:0;background-repeat:no-repeat;background-attachment:fixed}h1{font-size:34px;color:#222;font-family:Roboto,sans-serif;font-weight:900;margin:20px 0 30px 0;text-align:center}.content{text-align:center;font-family:Helvetica,Arial,sans-serif}@media(max-width:767px){h1{font-size:30px;margin:10px 0 30px 0}} </style>
<body>
</head>
<div class="wrapper">
<div class="inner">
<div class="header">
<h1><a href="#" title="{{ keyword }}">{{ keyword }}</a></h1>
<div class="menu">
<ul>
<li><a href="#">main page</a></li>
<li><a href="#">about us</a></li>
<li><a class="anchorclass" href="#" rel="submenu_services">services</a></li>
<li><a href="#">contact us</a></li>
</ul>
</div>
</div>
<div class="content">
{{ text }}
<br>
{{ links }}
</div>
<div class="push"></div>
</div>
</div>
<div class="footer">
<div class="footer_inner">
<p>{{ keyword }} 2021</p>
</div>
</div>
</body>
</html>";s:4:"text";s:19334:"A look at the s In the face of being in the red during last session for losing -4.93%, in the last five days KNSA remained trading in the green while hitting it’s week-highest on Monday, Apr 12 when the stock touched $17.71- price level, adding 11.74% to its value on the day. KINIKSA PHARMACEUTICALS, LTD. a Bermuda exempted company (“Licensee”). Kiniksa Pharmaceuticals | 7,965 followers on LinkedIn. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Relentless. Reviews from Kiniksa Pharmaceuticals employees about Kiniksa Pharmaceuticals culture, salaries, benefits, work-life balance, management, job security, and more. The P/E ratio of Kiniksa Pharmaceuticals is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In this conversation. Kiniksa Pharmaceuticals, Ltd. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Click here now. In March 2021, Kiniksa Pharmaceuticals had US$264m in cash, and was debt-free. Kiniksa is focused on developing medicines designed to modulate immunological pathways for patients suffering from debilitating diseases. The Plan goals are to be achiev. The primary business activity of the company is Pharmaceutical Preparations (SIC code 2834). Passionate. 2019-12-16: ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for: Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older. Get the latest Kiniksa Pharmaceuticals, Ltd. KNSA detailed stock quotes, … Separately, Zacks Investment Research cut Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in […] Benzinga Newsdesk, Benzinga Staff Writer {{following ? Kiniksa Pharmaceuticals Ltd is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. Kiniksa Pharmaceuticals, Ltd. March 18, 2021 GMT - ARCALYST is the first and only FDA-approved therapy for recurrent pericarditis - - Commercial launch expected in April 2021 - - Kiniksa launches Kiniksa One Connect™ patient support program - - Conference call and webcast scheduled for 5:30 p.m. EDT today - Focused | Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines designed for patients suffering from debilitating immunological diseases with significant unmet medical need. Kiniksa Pharmaceuticals, Ltd. insiders own 6.18% of total outstanding shares while institutional holders control 87.31%, with the float percentage being 93.07%. Market capitalization of Kiniksa Pharmaceuticals (KNSA) Market cap: $0.97 B As of May 2021 Kiniksa Pharmaceuticals has a market cap of $0.97 B.This makes Kiniksa Pharmaceuticals the world's 3752th most valuable company by market cap according to our data. In December 2020, Kiniksa Pharmaceuticals had US$323m in cash, and was debt-free. Kiniksa Pharmaceuticals Ltd. (KNSA) Fundamentals that are to be considered. KINIKSA PHARMACEUTICALS (UK), LTD. - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity ARCALYST® (rilonacept) is an interleukin-1 blocker indicated for: Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older. Chief Medical Officer, Kiniksa Pharmaceuticals Greater Boston. Offline. The stock has a consensus analyst rating of "Buy." Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals, Ltd. insiders own 6.18% of total outstanding shares while institutional holders control 87.31%, with the float percentage being 93.07%. Refresh. 3 Kiniksa Pharmaceuticals reviews. 01 Dec 2020 Kiniksa Pharmaceuticals completes a phase II trial in Giant cell arteritis in Australia, Belgium, Croatia, Estonia, Germany, Italy, Ireland, Netherlands, New Zealand, Poland, Serbia, Slovenia, Spain, USA and United Kingdom (NCT03827018) (EudraCT2018-001003-36) Total Kiniksa Pharmaceuticals Ltd earnings for the quarter were -$49.48 million. Kiniksa.com traffic volume is 15,102 unique daily visitors and their 75,510 pageviews. Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from … Verified account Protected Tweets @; Suggested users Kiniksa Pharmaceuticals employs 168 staff and has a market cap (total outstanding shares value) of 0.00. Kiniksa Pharmaceuticals Ltd Class A KNSA Morningstar%2c Inc. 5/7/2021 Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity Passionate. Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. Kiniksa Pharmaceuticals shares last traded at $14.07, with a volume of 149 shares traded. Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Kiniksa Pharmaceuticals Ltd. said Monday the U.S. Food and Drug Administration accepted the supplemental biologics license application for rilonacept in recurrent pericarditis. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity. Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs. View today's stock price, news and analysis for Kiniksa Pharmaceuticals Ltd. (KNSA). Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from … Adrian Smith Regional Sales Director at Kiniksa Pharmaceuticals Long Lake, MN. Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Hillhouse Capital Advisors Ltd. is the largest shareholder of the company, while 153 institutions own stock in it. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) trade information. Kiniksa Pharmaceuticals Ltd 's earnings in 2021 is -$184,446,000.On average, 3 Wall Street analysts forecast KNSA's earnings for 2021 to be $-186,499,357, with the lowest KNSA earnings forecast at $-210,837,819, and the highest KNSA earnings forecast at $-171,263,083. The company has an experienced management team, significant funding and a clear vision of building a global, generational company. Real time Kiniksa Pharmaceuticals Ltd (KNSA) stock price quote, stock graph, news & analysis. KNSA 13.54 0.32 (2.42%). Shares of Kiniksa Pharmaceuticals stock opened at $14.71 on Friday. Separately, Zacks Investment Research upgraded shares of Kiniksa Pharmaceuticals from a “strong sell” rating to […] Kiniksa Pharmaceuticals is ranked #39 on the Best Health Care Companies to Work For in Massachusetts list. Kiniksa Pharmaceuticals is hiring a Director, Compliance, with an estimated salary of $150,000 - $200,000. 68 talking about this. The all-time high Kiniksa Pharmaceuticals stock closing price was 30.93 on September 20, 2018.; The Kiniksa Pharmaceuticals 52-week high stock price is 28.67, which is 96% above the current share price. Passionate. Kiniksa is focused on developing medicines designed to modulate immunological pathways for patients suffering from debilitating diseases. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) price on Friday, Apr 23, dropped -0.67% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $16.43. Kiniksa Pharmaceuticals NewsMORE. Kite, a Gilead Company (Nasdaq: GILD), and Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”) announced today that the companies have entered in One the one hand we have its solid cash burn relative to … Kiniksa Pharmaceuticals also reported that weekly injections of rilonacept significantly reduced the number of pericarditis episodes over the six-month phase 2 … Kiniksa Pharmaceuticals | 8 348 abonnés sur LinkedIn. Hamilton HM11, Bermuda (808) 451-3453(Address, zip code and telephone number, including area code of principal executive offices) Kiniksa has already assembled an early stage pipeline and is actively looking to […] Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. Distributed by Public, unedited and unaltered, on 01 December 2020 20:20:04 UTC Hillhouse Capital Advisors Ltd. is the largest shareholder of the company, while 153 institutions own stock in it. A look at the s Online Status. Announces Proposed Public Offering HAMILTON, Bermuda, May 13, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa… Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is not the least popular stock in this group but hedge fund interest is still below average. Kiniksa Pharmaceuticals Ltd (KNSA): * KINIKSA ANNOUNCES POSITIVE RESULTS FOR MAVRILIMUMAB PHASE 2 TRIAL IN NON-MECHANICALLY VENTILATED SEVERE COVID-19 PATIENTS. 140 talking about this. Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from … How Long Is Kiniksa Pharmaceuticals' Cash Runway? Earnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($2.73) to ($2.13) per share. Manufactured by: Kiniksa Pharmaceuticals (UK), Ltd. London, UK W1S 4PZ U.S. License Number 2236 Instructions for Use ARCALYST ® (ARK-a-list) … It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals, Ltd. Clarendon House. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Kiniksa Pharmaceuticals Ltd - Class A share forecasts, stock quote and buy / … How Long Is Kiniksa Pharmaceuticals' Cash Runway? View the latest ratings for KNSA. Kiniksa Pharmaceuticals | LinkedInのフォロワー数8,999人Relentless. Description: Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Respiratory Distress Syndrome Market Will Grow at a Healthy With Top Key Players – Kiniksa Pharmaceuticals, CytoDyn, Alexion Pharmaceuticals. Find real-time KNSA - Kiniksa Pharmaceuticals Ltd stock quotes, company profile, news and forecasts from CNN Business. We have conducted a comparative analysis of the balance sheet and the income statement of Kiniksa Pharmaceuticals, Ltd. (hereafter – the "Company") for the year 2020 submitted to the U.S. Securities and Exchange Commission (SEC). View Kiniksa Pharmaceuticals, Ltd. KNSA investment & stock information. Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) stock closed at 14 per share at the end of the most recent trading day (a -0.92 % change compared to the prior day closing price) with a volume of 198.07K shares and market capitalization of 976.40M.Is a component of indices and it is traded on NASDAQ exchange. Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Uncover why Kiniksa Pharmaceuticals is the best company for you. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s Biggest Investors. About Kiniksa. Kiniksa Pharmaceuticals is hiring a Associate Director, Quality Control, with an estimated salary of $100,000 - $150,000. Kiniksa Pharmaceuticals' stock is trading down $0.06 today. Kiniksa Pharmaceuticals appears to be in pretty good health when it comes to its cash burn situation. Kiniksa Pharmaceuticals, Ltd. * Kiniksa Pharmaceuticals Ltd (KNSA) - ENROLLMENT IN PHASE 3 … Company profile for Kiniksa Pharmaceuticals Ltd. including key executives, insider trading, ownership, revenue and average growth rates. HAMILTON, Bermuda, July 21, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. ( KNSA) (“Kiniksa,” “we,” and “our”) announced today the pricing of its public offering of 5,952,381 Class A common shares at a public offering price of $21.00 per share, … Kiniksa is responsible for sales and distribution of ARCALYST for all the approved indications in the United States, including cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA), and will evenly split profits with Regeneron Pharmaceuticals, Inc. (Regeneron). Corporate Governance Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of April 30, 2021 is 10. Kiniksa Pharmaceuticals @kiniksa Every Second Counts! KINIKSA PHARMACEUTICALS (UK), LTD. - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity "Following" : "Follow"}} … Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) shares hit a new 52-week low on Thursday . The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -6.21 and a … In December 2020, Kiniksa Pharmaceuticals had US$323m in cash, and was debt-free. Relentless. Relentless. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Kiniksa Pharmaceuticals Ltd - Class A () Stock Market info Recommendations: Buy or sell Kiniksa Pharmaceuticals Ltd - Class A stock? Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with a significant unmet medical need. Kiniksa Pharmaceuticals NASDAQ Updated May 27, 2021 9:32 PM. Kiniksa Pharmaceuticals (KNSA) reported a 1st Quarter March 2021 loss of $0.72 per share on revenue of $0.0 million. More Details The company belongs in the Biotechnology industry, Healthcare sector and … Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Auditor's conclusion. The latest closing stock price for Kiniksa Pharmaceuticals as of May 07, 2021 is 14.63.. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. Kiniksa Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved its ARCALYST injection therapy as a first-of-its-kind treatment for adults and children 12 years and older with recurrent pericarditis and the reduction in risk of recurrence. Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. In the same quarter last year, Kiniksa Pharmaceuticals Ltd's earnings per share (EPS) was -$0.48. Passionate. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s Biggest Investors. Kiniksa Pharmaceuticals, Ltd. operates as a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating dise ases. Does Kiniksa Pharmaceuticals Have A Long Cash Runway? Relentless. The Company focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. This Kiniksa Pharmaceuticals, Ltd. Rilonacept Long-Term Incentive Plan (the “Plan”) is intended to increase stockholder value and the success of the Company by motivating and retaining selected Participants to achieve the Company’s objectives. Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Focused | Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines designed to modulate immunological signaling pathways for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Q1 EPS $(0.72) Down From $(0.48) YoY. At Stash, we don’t recommend trying to predict the market when buying investments. The stock had previously closed at $15.04. Passionate. Data Bridge Market Research February 24, … When analyzing a stock, the first fundamental thing to take into account is the balance sheet. Kiniksa Pharmaceuticals | 8,482 followers on LinkedIn. A. Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with … View detailed KNSA description & address. Post-Market 0.04 (0.30%) Acute Respiratory Distress Syndrome Market is expecting massive CAGR of +9% for the term of 2021-28. Kiniksa Pharmaceuticals, Ltd. reported fiscal year 2019 executive compensation information on April 28, 2020. Kiniksa Pharmaceuticals Ltd. published this content on 30 November 2020 and is solely responsible for the information contained therein. Real time Kiniksa Pharmaceuticals Ltd (KNSA) stock price quote, stock graph, news & analysis. Kiniksa Pharmaceuticals' current and average target prices are 20.90 and 35.00, respectively. Kiniksa Pharmaceuticals is a privately held biotechnology company focused on developing and delivering therapeutics to patients with devastating diseases and unmet medical needs. Distributed by Public, unedited and unaltered, on 12 April 2021 12:22:02 UTC. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. The consensus estimate was a … Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) reported Q1 2021 earnings per share (EPS) of -$0.72, up 50% year over year. ";s:7:"keyword";s:23:"kiniksa pharmaceuticals";s:5:"links";s:624:"<a href="http://sljco.coding.al/rlyldfr/anterior-ischemic-optic-neuropathy-icd-10">Anterior Ischemic Optic Neuropathy Icd-10</a>,
<a href="http://sljco.coding.al/rlyldfr/kenya-livestock-research-institute">Kenya Livestock Research Institute</a>,
<a href="http://sljco.coding.al/rlyldfr/where-is-last-man-standing-supposed-to-be-located">Where Is Last Man Standing Supposed To Be Located</a>,
<a href="http://sljco.coding.al/rlyldfr/carnival-overture-tambourine-excerpt">Carnival Overture Tambourine Excerpt</a>,
<a href="http://sljco.coding.al/rlyldfr/1812-overture-sheet-music-violin">1812 Overture Sheet Music Violin</a>,
";s:7:"expired";i:-1;}
Mini Shell